Rhee Thomas K, Omary Reed A, Gates Vanessa, Mounajjed Taofic, Larson Andrew C, Barakat Omar, Sato Kent T, Mulcahy Mary, Gordon Stuart, Lewandowski Robert J, Salem Riad
Section of Interventional Radiology, Department of Radiology, Henry Ford Hospital, Detroit, MI, USA.
J Vasc Interv Radiol. 2005 Aug;16(8):1085-91. doi: 10.1097/01.RVI.0000177063.92678.21.
Yttrium 90 radioembolization is a transcatheter therapy for unresectable hepatocellular carcinoma (HCC) that delivers internal radiation to tumors. In contrast to the usual method of lobar regional delivery, catheter-directed computed tomographic (CT) angiography was investigated as a potentially useful technique to evaluate the administration of segmental 90Y tumor radiation doses superselectively without significantly altering liver function or Child-Pugh classification.
Fourteen patients underwent 90Y therapy for unresectable HCC. After standard angiographic placement of a 3-F microcatheter in a segmental hepatic artery supplying the tumor, each patient underwent CT angiography with use of segmental hepatic artery injection of iodinated contrast agent to confirm segmental perfusion and delineate segmental liver volume. 90Y was later injected into the same segmental artery. Target dose was calculated according to infused 90Y activity and targeted hepatic volume with standard lobar volume (before CT angiography) versus segmental liver volume (after CT angiography). The Wilcoxon signed-rank test (alpha = 0.05) was used to compare the estimated 90Y dose before CT angiography with the actual 90Y dose after CT angiography, as well as changes in serum bilirubin level and Child-Pugh classification as a result of treatment.
The mean estimated tumor dose before CT angiography (SD) was 100 Gy +/- 43 (range, 35-169 Gy). The mean actual tumor dose after CT angiography was 348 Gy +/- 204 (range, 105-857 Gy), which was significantly greater (P < .001). The mean bilirubin level before treatment was 1.0 mg/dL +/- 0.97 (range, 0.2-4.0 mg/dL), whereas the mean bilirubin level after treatment was 1.3 mg/dL +/- 0.85 (range, 0.5-3.8 mg/dL). This difference, although statistically significant (P = .03), was not clinically important. Thirteen of 14 patients had no change in Child-Pugh class.
CT angiography can be used to delineate the blood supply and volume to a targeted hepatic segment, allowing superselective 90Y radioembolization. This approach significantly increases effective 90Y tumor radiation dose without clinically altering liver function or Child-Pugh class.
钇90放射性栓塞是一种针对不可切除肝细胞癌(HCC)的经导管治疗方法,可对肿瘤进行内照射。与通常的叶区域给药方法不同,导管导向计算机断层扫描(CT)血管造影被作为一种潜在有用的技术进行研究,以评估在不显著改变肝功能或Child-Pugh分级的情况下超选择性给予肝段90Y肿瘤辐射剂量。
14例不可切除HCC患者接受了90Y治疗。在将3F微导管通过标准血管造影术放置在供应肿瘤的肝段动脉后,每位患者通过肝段动脉注射碘化造影剂进行CT血管造影,以确认肝段灌注并描绘肝段肝脏体积。随后将90Y注入同一肝段动脉。根据注入的90Y活度和目标肝脏体积计算目标剂量,分别采用标准叶体积(CT血管造影前)和肝段肝脏体积(CT血管造影后)。采用Wilcoxon符号秩检验(α = 0.05)比较CT血管造影前估计的90Y剂量与CT血管造影后实际的90Y剂量,以及治疗后血清胆红素水平和Child-Pugh分级的变化。
CT血管造影前估计的平均肿瘤剂量(标准差)为100 Gy±43(范围35 - 169 Gy)。CT血管造影后平均实际肿瘤剂量为348 Gy±204(范围105 - 857 Gy),显著更高(P <.001)。治疗前平均胆红素水平为1.0 mg/dL±0.97(范围0.2 - 4. mg/dL),而治疗后平均胆红素水平为1.3 mg/dL±0.85(范围0.5 - 3.8 mg/dL)。这种差异虽然具有统计学意义(P =.03),但在临床上并不重要。14例患者中有13例Child-Pugh分级无变化。
CT血管造影可用于描绘目标肝段的血供和体积,从而实现超选择性90Y放射性栓塞。这种方法可显著提高有效的90Y肿瘤辐射剂量,而不会在临床上改变肝功能或Child-Pugh分级。